ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...
Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3’2024 Year-to-date revenue of $22.8 million, a 26% increase compared to the first nine months of 2024 Total Cash of $13.2 million as ...
ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue ...
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness ...
ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a commercial-stage bioelectronic medicine Company and wellness company, today ...
ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the ...
Zacks.com on MSN
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
electroCore, Inc. (ECOR) shares soared 7.1% in the last trading session to close at $6.65. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 ...
ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual ...
ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a bioelectronic technology company, today announced full year 2025 financial ...
electroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients electroCore anticipates results of the company’s two clinical studies on ...
BASKING RIDGE, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results